Table of Contents
- Trial overview
- Safe discontinuation in remitted depression
- Personalized treatment after prior failure
- Main outcomes and measures
- Who can participate
- What these trials may mean for patients
Trial overview
Two authorised Phase 3 clinical trials include Venlafaxine Hydrochloride in research on depressive disorders.[1][1] Both studies are interventional, which means researchers are testing a planned treatment strategy and measuring the results.[1][1]
One study focuses on people with currently remitted depressive disorders and looks at antidepressant discontinuation.[1] The other study focuses on people with depressive disorder who are starting a new antidepressant after prior treatment failure.[1]
Safe discontinuation in remitted depression
The first trial is titled SAFE DISCONTINUATION OF ANTIDEPRESSANTS IN INDIVIDUALS WITH CLINICALLY REMITTED DEPRESSIVE DISORDERS.[1] It is authorised, Phase 3, and plans to enroll 150 participants with currently remitted depressive disorders.[1]
This study compares hyperbolic tapering with linear tapering.[1] Tapering means lowering the medicine step by step before stopping it.[1] The study checks whether people can discontinue the antidepressant successfully and stay off it during the 16 weeks after stopping.[1]
The primary outcome is the proportion of participants who fail to discontinue the antidepressant or restart it during the 16-week follow-up.[1] Failure to discontinue is defined as continuing the medication beyond the planned tapering schedule, with only a small tolerance period allowed.[1] This may happen because of withdrawal symptoms or because depressive or anxiety symptoms return.[1]
The listed antidepressants in this trial include several medicines used in oral form, and Venlafaxine Hydrochloride is part of the broader research topic for this article.[1]
Personalized treatment after prior failure
The second trial is the PREDICT clinical trial, which is also authorised and in Phase 3.[1] It plans to enroll 240 participants with depressive disorder.[1]
This study evaluates a pre-emptive pharmacogenetic strategy for antidepressant selection.[1] Pharmacogenetic testing means looking at genetic markers to help choose a medicine before treatment starts.[1] The study compares this personalized approach with standard clinical practice in people who are beginning a new antidepressant after a previous treatment did not work.[1]
Venlafaxine Hydrochloride appears in the trial’s list of possible antidepressant options as Venlafaxina Retard Sandoz 75 mg, a prolonged-release capsule.[1] The trial does not study Venlafaxine Hydrochloride alone; it is part of a larger treatment-selection strategy.[1]
Main outcomes and measures
In the discontinuation trial, the main outcome is whether participants can stop the antidepressant and avoid restarting it during the follow-up period.[1] This outcome helps researchers understand how well different tapering methods support safe stopping.[1]
In the PREDICT trial, the main outcome is symptom remission after starting a new antidepressant treatment.[1] Researchers measure this using changes in PHQ-9 and MADRS scores, which are tools for rating depression severity.[1]
These outcomes focus on two important questions: can treatment be stopped safely, and can treatment choice be improved for better symptom control?[1][1]
Who can participate
The first study is for adults with currently remitted depressive disorders.[1] This means people whose depression is currently improved enough to be considered in remission.[1]
The second study is for patients with depressive disorder who are starting a new antidepressant after a prior therapy failed.[1] The study also uses demographic information, clinical information, and data about other medicines taken at the same time.[1]
- Remitted depression group: people whose depressive disorder is currently not active, so researchers can study stopping antidepressants safely.[1]
- Depressive disorder group: people who need a new antidepressant after a previous treatment failure, so researchers can test a personalized selection strategy.[1]
What these trials may mean for patients
These studies are not simple drug comparison trials; they test treatment strategies in real clinical situations.[1][1] One strategy asks whether antidepressants can be stopped more safely after remission, while the other asks whether treatment choice can be improved using genetic and clinical information.[1][1]
For patients, the most important point is that the trials are looking at practical outcomes such as staying well, avoiding symptom return, and matching treatment to the person.[1][1] The available data show that Venlafaxine Hydrochloride is part of this broader depression research, especially in treatment planning and antidepressant selection.[1]
